Kit and diagnostic system for detecting type 2 diabetes mellitus
By detecting the L-glutamine concentration in serum small extracellular vesicles, using gas-phase-mass spectrometry and immunoenzyme-linking method, combined with systematic data processing, the problem that traditional methods cannot diagnose type 2 diabetes early is solved, and achieves the goal of achieving the problem of traditional methods being unable to diagnose type 2 diabetes. Higher diagnostic accuracy and stability.
Patent Information
- Application Number
- CN202411210149.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-30
- Publication Date
- 2024-12-03
AI Technical Summary
Traditional methods cannot effectively predict or early suggest the occurrence of type 2 diabetes. Existing detection methods have poor stability for serum DNA or non-coding RNA, making it difficult to provide reliable diagnostic tools.
By detecting the L-glutamine concentration in small extracellular vesicles in serum, using gas-phase-mass spectrometry and immunoenzyme-linking method, combining the data collection, differential diagnosis module and interactive module system, the system of type 2 diabetes is established. Early diagnosis method.
It provides a new and highly stable detection target, which significantly improves the accuracy of early diagnosis and prognosis judgment ability of type 2 diabetes, and is better than traditional methods.
Smart Images

Figure CN119064587A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of clinical medicine, and in particular relates to a kit for detecting type 2 diabetes and a diagnostic system. Background Art
[0002] Studies in recent years have found that there is a kind of nano-scale membrane vesicle in body fluids, namely small extracellular vesicles (sEVs). It is produced by cells and can enrich various components in cells such as proteins, nucleic acids, metabolites, etc. It exists in various body fluids and can participate in regulating the occurrence and development of many complex metabolic diseases. It has now been proven to be used for early diagnosis and efficacy observation of many intractable diseases.
[0003] Diabetes is a metabolic disease characterized by increased blood sugar, which can induce a variety of serious acute and chronic complications, of which more than 90% are type 2 diabetes mellitus (T2DM). T2DM has an insidious onset, and early prevention and treatment are of great significance for controlling the progression of the disease. However, traditional methods have a clear diagnosis of T2DM, but cannot predict or indicate the occurrence of diabetes as early as possible, which is not very helpful for the prevention and treatment of the disease. Using DNA or non-coding RNA in serum as a detection target is easily affected by environmental factors and has poor stability. It is now urgent to provide a detection method and kit for detecting type 2 diabetes. Summary of the invention
[0004] In view of this, the present invention provides a use of L-glutamine in serum small extracellular vesicles in the preparation of a kit for detecting type 2 diabetes.
[0005] Also provided is a kit for detecting type 2 diabetes, the kit comprising a reagent for extracting serum small extracellular vesicles, a reagent for extracting metabolites of small extracellular vesicles, and a reagent for detecting L-glutamine.
[0006] Optionally, the above-mentioned L-glutamine detection reagent includes a gas chromatography-mass spectrometry-based L-glutamine detection reagent or an immunoenzyme-linked assay-based L-glutamine detection reagent.
[0007] A system for diagnosing type 2 diabetes, the system comprising a data collection module, a differential diagnosis module, an interaction module and a data storage module; the data collection module comprises a unit for collecting information on the L-glutamine concentration in serum small extracellular vesicles of a subject.
[0008] In the above system, obtaining the information of L-glutamine concentration in serum small extracellular vesicles comprises the following steps:
[0009] a. Extracting small extracellular vesicles from serum;
[0010] b. Small extracellular vesicle sample processing;
[0011] c. Detect the L-glutamine concentration in the sample.
[0012] Optionally, the method for extracting small extracellular vesicles in serum in step a is selected from any one or more of ultracentrifugation, molecular size exclusion chromatography and immunoadsorption.
[0013] Optionally, the method for processing the small extracellular vesicle sample in step b is selected from any one or more of steel bead grinding and ultrasonic disruption.
[0014] Optionally, the method for detecting the concentration of L-glutamine in the sample in step c is selected from any one or more of gas chromatography-mass spectrometry and immunoassay.
[0015] In the above system, the differential diagnosis module includes comparing the data collected by the data collection module with the diagnostic criteria to determine the possibility that the subject is ill.
[0016] The above diagnostic criteria are to establish a control standard by analyzing sample data from a large number of healthy people. If the subject's data is significantly higher than the control standard, it is considered that the subject has a high possibility of suffering from type 2 diabetes.
[0017] Beneficial effects:
[0018] The present invention uses gas chromatography-mass spectrometry (GC-MS) and enzyme linked immunosorbent assay (ELISA) to detect serum small extracellular vesicle L-glutamine in healthy people, early T2MD and newly diagnosed T2DM patients for the first time, and reveals that serum small extracellular vesicle L-glutamine can provide new clues and relevant research basis for the early diagnosis and prognosis of T2DM.
[0019] The present invention obtains a new target that can be used for the early diagnosis of type 2 diabetes by detecting L-glutamine in serum small extracellular vesicles of patients with newly diagnosed type 2 diabetes, patients with early type 2 diabetes and healthy controls. The new target has high stability and good detection effect, and the diagnostic effect is better than that of existing conventional diagnostic tests. BRIEF DESCRIPTION OF THE DRAWINGS
[0020] Figure 1 : Schematic diagram of the overall modules of the system for diagnosing type 2 diabetes.
[0021] Figure 2: Characterization and identification of serum sEVs, A: Nanosight visual nanoparticle analyzer detects the diameter distribution of sEVs; B: sEVs morphology under transmission electron microscopy, Bar: 100nm; C: Western-blot detection of sEVs surface markers CD9, CD81, Alix and Calnexin.
[0022] Figure 3 : Quantitative results of L-Gln targeted metabolomics (n=6) (*P<0.05, **P<0.01, ***P<0.001, ****P<0.0001).
[0023] Figure 4 : Quantitative results of L-Gln ELISA (n=36) (*P<0.05, **P<0.01, ***P<0.001, ****P<0.0001). DETAILED DESCRIPTION
[0024] The present invention provides an application of L-glutamine in serum small extracellular vesicles in preparing a kit for detecting type 2 diabetes.
[0025] The present invention provides a kit for detecting type 2 diabetes, which comprises a reagent for extracting serum small extracellular vesicles, a reagent for extracting metabolites of the small extracellular vesicles, and a reagent for detecting L-glutamine.
[0026] Preferably, the above-mentioned reagent for extracting serum small extracellular vesicles is Exosome Isolation Reagent (from serum) kit.
[0027] Optionally, the above-mentioned L-glutamine detection reagent includes a gas chromatography-mass spectrometry-based L-glutamine detection reagent or an immunoenzyme-linked assay-based L-glutamine detection reagent.
[0028] A system for diagnosing type 2 diabetes, the system comprising a data collection module, a differential diagnosis module, an interaction module and a data storage module (such as Figure 1 As shown); the data collection module includes a unit for collecting information on the L-glutamine concentration in the subject's serum small extracellular vesicles.
[0029] Optionally, the data collection module further includes a basic information collection unit, which is used to collect basic information of the subject, including age, gender, medical history and family medical history information.
[0030] In the above system, obtaining the information of L-glutamine concentration in serum small extracellular vesicles comprises the following steps:
[0031] a. Extracting small extracellular vesicles from serum;
[0032] b. Small extracellular vesicle sample processing;
[0033] c. Detect the L-glutamine concentration in the sample.
[0034] Optionally, the method for extracting small extracellular vesicles in serum in step a is selected from any one or more of ultracentrifugation, molecular size exclusion chromatography and immunoadsorption.
[0035] Optionally, the method for processing the small extracellular vesicle sample in step b is selected from any one or more of steel bead grinding and ultrasonic disruption.
[0036] Optionally, the method for detecting the concentration of L-glutamine in the sample in step c is selected from any one or more of gas chromatography-mass spectrometry and immunoassay.
[0037] In the above system, the interaction module is used to provide an interaction interface for doctors and subjects;
[0038] In the above system, the data storage module is used to store the subject information and the disease analysis results;
[0039] In the above system, the differential diagnosis module includes comparing the data collected by the data collection module with the diagnostic criteria to determine the possibility that the subject is ill.
[0040] The above diagnostic criteria are to establish a control standard by analyzing sample data from a large number of healthy people. If the subject's data is significantly higher than the control standard, it is considered that the subject has a high possibility of suffering from type 2 diabetes.
[0041] In the present invention, unless otherwise specified, all raw material components are commercially available products well known to those skilled in the art.
[0042] The following will be combined with the embodiments of the present invention to clearly and completely describe the technical solutions of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of them. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0043] Example 1
[0044] 1. Standards and Reagents
[0045] An appropriate amount of L-glutamine standard was accurately weighed using an analytical balance and dissolved in water to obtain a standard stock solution. The concentration of the stock solution was 1 mg / mL. A mixed standard solution was prepared using the standard stock solution, and the mixed standard solution was gradiently diluted to obtain a standard curve.
[0046] Table 1 Reagents used
[0047]
[0048] 2. Experimental subjects
[0049] 2.1 Samples were selected from 180 people who underwent physical examinations at the Health Management Center and the Department of Endocrinology of Yixing Hospital Affiliated to Jiangsu University from January 2022 to December 2023 as research subjects, including 36 healthy controls (negative controls, NCs), 36 IFG (pre-T2DM) patients, 36 new T2DM patients, 36 patients with dyslipidemia (Dys), and 36 patients with dyslipidemia combined with T2DM (T2DM-Dys). All patients were Han adults aged over 18 years old, and all experimental specimens were biological specimens obtained during clinical diagnosis and treatment. The relevant procedures were approved by the Ethics Committee of Yixing Hospital Affiliated to Jiangsu University and met the standards.
[0050] Table 2 Clinical characteristics of the experimental population
[0051]
[0052] 2.2 Diagnostic criteria
[0053] (1) Diagnostic criteria for abnormal FPG: Referring to the "Guidelines for the Prevention and Treatment of Type 2 Diabetes in China (2020 Edition)", FPG < 6.1 mmol / L is defined as "normal blood sugar"; 6.1 ≤ FPG < 7.0 mmol / L is defined as "IFG"; and FPG ≥ 7.0 mmol / L is defined as "T2DM".
[0054] (II) New-onset T2DM diagnostic criteria: The T2DM diagnostic criteria established by the World Health Organization (WHO) in 1999 were adopted: typical symptoms of diabetes plus random blood glucose ≥ 11.1mmol / L or fasting blood glucose ≥ 7.0mmol / L or blood glucose ≥ 11.1mmol / L 2 hours after 75g glucose load; patients without diabetes symptoms should be confirmed by repeating the examination on another day. Combined with the duration of disease of all patients ≤ 6 months, the new-onset T2DM diagnostic criteria were used.
[0055] (III) Diagnostic criteria for dyslipidemia: With reference to the diagnostic criteria for dyslipidemia in the Guidelines for the Prevention and Treatment of Dyslipidemia in Adults in China (2016 Revised Edition), dyslipidemia was diagnosed if at least one of the following abnormal blood lipid metabolism conditions was met, specifically in combination with the linear range of blood lipid index detection in our hospital: total cholesterol (TC) ≥5.17 (0-5.17 mmol / L), triglyceride (TG) ≥2.3 (0-2.3 mmol / L), low-density lipoprotein cholesterol (LDL-C) ≥3.1 (0-3.1 mmol / L) or high-density lipoprotein cholesterol (HDL-C) <1.1 (1.1-1.74 mmol / L).
[0056] (IV) Diagnostic criteria for T2DM combined with dyslipidemia: It is sufficient to meet both the above diagnostic criteria for new-onset T2DM and the diagnostic criteria for dyslipidemia.
[0057] (V) (1) Patients with T1DM, gestational diabetes, secondary diabetes and other special types of diabetes;
[0058] (2) Patients with diabetes mellitus complicated by other diseases other than dyslipidemia;
[0059] (3) patients who had used systemic glucocorticoids in the last 3 months;
[0060] (4) Patients with serious mental illness, malignant tumors, autoimmune diseases, hypertension, liver cirrhosis, etc.
[0061] 3. Extraction of serum small extracellular vesicles (sEVs)
[0062] 3.1. Serum specimen collection: The subjects were starved overnight, and 5 mL of serum was collected from the biochemical tubes and dispensed into EP tubes and stored in a -80°C refrigerator.
[0063] 3.2. Extraction of sEVs: Utilization Extract sEVs using the Exosome Isolation Reagent (from serum) kit. Centrifuge the serum sample at 2000g for 30 minutes at room temperature to remove residual cells and cell debris. Transfer the supernatant to a new centrifuge tube, being careful not to aspirate the bottom precipitate. Place the centrifuge tube on ice until use. Use a pipette to transfer the required volume of serum sample to a new tube, add 1 / 5 of the serum volume of VEX Exosome Isolation Reagent (from serum); invert or pipette to mix the reagent until the solution is fully mixed, and the mixed solution is turbid. The mixture was placed vertically at 2-8°C for 30 min. After incubation, centrifuged at 10,000 g for 5 min at 4°C. The supernatant was carefully removed with a pipette. The serum sEVs were present in the precipitate at the bottom of the tube. The tube wall and the precipitate surface were slowly washed with PBS twice. The PBS was immediately removed and centrifuged at 10,000 g for 30 s at 4°C. The supernatant was removed with a pipette. The sEVs precipitate can be directly stored in a -80°C refrigerator or resuspended with an appropriate amount of PBS, aliquoted and stored in a -80°C refrigerator for subsequent experiments.
[0064] Example 2
[0065] Detection, characterization and identification of serum sEVs:
[0066] The diameter of serum sEVs extracted from Example 1 was detected by Nanosight visual nanoparticle analyzer. Figure 2 As shown in A, the average diameter of T2DM-sEVs is approximately 188.2±4.70nm, and the average diameter of NC-sEVs is approximately 162.4±6.78nm.
[0067] like Figure 2 As shown in B, under transmission electron microscopy, sEVs are approximately 110 nm in diameter, have a complete cell membrane, and have a low electron density component in the cavity. Their shape is "saucer-shaped" or "oval-shaped", which is consistent with the morphological characteristics of sEVs (marked by the red arrow).
[0068] like Figure 2 As shown in C, Western-Blot detected the marker proteins CD9, CD81, Alix and Calnexin of sEVs, and all of them except Calnexin were expressed in both groups of sEVs.
[0069] The above results indicate that high-quality serum sEVs were extracted and enriched in Example 1.
[0070] Example 3
[0071] Quantitative analysis of serum sEVs L-Gln by gas chromatography-mass spectrometry (GC-MS):
[0072] 1. Sample pretreatment:
[0073] (1) Weigh 0.10 g of the sEVs sample prepared in Example 1 and place it into a 1.5 mL EP tube (the EP tube was precooled at -20°C);
[0074] (2) Add 400 μL methanol-acetonitrile;
[0075] (3) Add two small steel balls, place in a -20°C refrigerator for 2 min, and grind in a grinder;
[0076] (4) Ultrasonication in an ice bath for 10 min, and then standing at -20°C for 30 min;
[0077] (5) Centrifuge for 10 min, take 100 μL of the supernatant and evaporate to dryness in a wide liner tube;
[0078] (6) QC was prepared by mixing equal volumes of extracts from all samples;
[0079] (7) Add 80 μL of methoxyamine hydrochloride pyridine solution to the glass derivatization vial, vortex for 2 min, and then place in a shaking incubator at 37 °C for oximation reaction;
[0080] (8) After taking out the sample, add 80 μL of bis(trimethylsilyl)trifluoroacetamide derivatization reagent and 20 μL of n-hexane, vortex thoroughly for 2 min, and react at 70 °C for 1 h;
[0081] (9) After taking out the samples, they were placed at room temperature for 0.5 h and then subjected to GC-MS targeted metabolomics analysis.
[0082] 2.GC-MS analysis:
[0083] The analytical instrument used for GC-MS analysis was the Thermo Fisher TSQ9000 gas spectrometer. Chromatographic conditions: DB-5MS capillary column, carrier gas was high-purity helium, flow rate was 1.2mL / min, and injection port temperature was 260℃. The injection volume was 1μL, non-split injection, and solvent delay was 4min. The column oven was set at an initial temperature of 50℃, maintained for 0.5min, and then programmed to increase the temperature. Mass spectrometry conditions: electron bombardment ion source temperature was 300℃, transfer line temperature was 280℃, scanning mode was selected reaction detection scanning, and mass scanning range was: m / z: 40-600. Metabolite quantification was analyzed using the multiple reaction detection mode of triple quadrupole mass spectrometry. The default parameters in TraceFinder4.1General Quan software were used to automatically identify and integrate each ion fragment, and manual inspection was assisted. The repeatability of metabolite detection was judged by overlapping the total ion current (TIC) graph of mass spectrometry analysis of different QC samples. According to the retention time and peak type information of the metabolites, the mass spectrometry peaks detected for each metabolite in different samples were manually corrected. And according to the peak area of the metabolites, the standard curves of different metabolites, and the sampling and (or) dilution multiples and other parameters, the absolute content information of each metabolite in the actual sample was obtained.
[0084] In order to verify the difference of L-Gln among different groups, quantitative analysis was performed based on targeted metabolomics, and statistical difference analysis was performed. The results are shown in Figure 3 As shown in the data, compared with the control group, the expression levels of L-Gln in serum sEVs were significantly increased in the IFG group, T2DM group, Dys group and T2DM-Dys group, and the differences were statistically significant (P<0.05), and the expression of L-Gln was the highest in the IFG group.
[0085] Considering that the sample size of targeted metabolomics is small (n=6 for each group), its results cannot reflect the overall characteristics well, which may affect the accuracy of the study. Therefore, the ELISA method was further used to verify a larger sample size (n=36 for each group).
[0086] Example 4
[0087] Quantitative analysis of serum sEVs L-Gln by immunoenzyme-linked immunosorbent assay (ELISA):
[0088] 1. Sample processing method:
[0089] Add 500 μL of 50% methanol (cooled to 4°C) to the sEVs precipitate, flick the precipitate, blow and shake for 30 seconds to mix the sample. Place on ice for 30 minutes, then place the EP tube in liquid nitrogen for 1 minute, completely thaw in an ice bath and sonicate for 5 minutes (repeat five times). Then let it stand for 5 minutes to extract metabolites from sEVs, centrifuge at 14000g for 15 minutes at 4°C to separate the extracted metabolites, and freeze-dry the supernatant containing the metabolites. The final dried sample powder is the metabolite and is stored at -80°C until analysis (using autoclaved ddH 2 O dissolved).
[0090] 2. Elisa test:
[0091] The imported L-Glutamine ELISA Kit was used. The assay was performed according to the instructions. The specific steps are as follows:
[0092] (1) Add 50 μL of the corresponding standard solution, blank sample diluent, and sample solution to a 96-well ELISA plate. The solution should be added to the bottom of the ELISA plate wells, avoiding contact with the inner wall and bubbling.
[0093] (2) Immediately add 50 μL of Detection Reagent A working solution to each well, cover with a sealing film, tap the plate gently to ensure thorough mixing, and incubate at 37°C for 1 h. If Detection Reagent A appears turbid, warm to room temperature until the solution is homogeneous.
[0094] (3) Inject washing buffer (about 400 μL) into each well and let it stand in the well for 1-2 minutes. Repeat this process 3 times. All liquid must be removed at each step. After the last wash, the remaining washing buffer must be completely removed. Invert the plate and tap it on a clean thick absorbent paper.
[0095] (4) Add 100 μL of detection reagent B working solution to each well, cover with sealing film, and incubate at 37°C for 45 min.
[0096] (5) Repeat the cleaning process in step (3) 5 times.
[0097] (6) Add 90 μL of matrix solution to each well in a dark place, cover with a new sealing film, and incubate at 37°C for 10-20 min. The reaction time can be shortened or extended according to the actual color change, but should not exceed 30 min.
[0098] (7) Add 50 μL of stop solution to each well.
[0099] (8) Use an Infinite F50 microplate reader to read the absorbance (OD value) of each well at a wavelength of 450 nm.
[0100] (9) Draw a standard curve and calculate the content of L-Gln in each sample.
[0101] ELISA quantitative results are as follows Figure 4 As shown in the figure, the expression of L-Gln in serum sEVs of the IFG group, T2DM group and T2DM-Dys group was higher than that of the NC group, and the expression of L-Gln in serum sEVs of the T2DM-Dys group was higher than that of the Dys group. The differences in these two comparisons were statistically significant (P<0.05). Although the mean expression of L-Gln in serum sEVs of patients in the Dys group was also higher than that in the NC group, there was no statistical difference (P>0.05). This shows that the expression of L-Gln in serum sEVs of patients is correlated with glycolipid disorders, and is mainly closely related to impaired glucose metabolism in patients.
[0102] In general, due to the different metabolite extraction and detection methods of targeted metabolomics and ELISA samples, the L-Gln concentration in sEVs of samples detected by ELISA was lower than that of targeted metabolomics, but the trends were consistent.
[0103] In summary, whether it is the results of targeted metabolomics or the results of ELISA, the mean expression of L-Gln in serum sEVs of patients in the IFG group is always the highest among all groups, and it is also the most significant in the NC group (P<0.0001 for both methods). The consistency of the trend of the results of the two groups of methods also illustrates the feasibility of ELISA method to detect the content of L-Gln in serum sEVs. Based on the above results, L-Gln in serum sEVs can become a new diagnostic biomarker for IFG patients.
[0104] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.
Claims
1. An application of L-glutamine in serum small extracellular vesicles in the preparation of a kit for detecting type 2 diabetes.
2. A kit for detecting type 2 diabetes, characterized in that: The kit comprises a reagent for extracting serum small extracellular vesicles, a reagent for extracting and detecting metabolites of small extracellular vesicles, and a reagent for detecting L-glutamine.
3. The kit according to claim 2, characterized in that The L-glutamine detection reagent includes a gas phase-mass spectrometry-based L-glutamine detection reagent or an immunoenzyme-linked method-based L-glutamine detection reagent.
4. A system for diagnosing type 2 diabetes, characterized in that: The system includes a data collection module, a differential diagnosis module, an interaction module and a data storage module; the data collection module includes a unit for collecting information on the L-glutamine concentration in serum small extracellular vesicles of a subject.
5. The system according to claim 4, characterized in that The acquisition of information on the concentration of L-glutamine in serum small extracellular vesicles comprises the following steps: a. Extracting small extracellular vesicles from serum; b. Small extracellular vesicle sample processing; c. Detect the L-glutamine concentration in the sample.
6. The system according to claim 5, characterized in that The method for extracting small extracellular vesicles in serum in step a is selected from any one or more of ultracentrifugation, molecular size exclusion chromatography and immunoadsorption.
7. The system according to claim 5, characterized in that The method for processing the small extracellular vesicle sample in step b is selected from any one or more of steel bead grinding and ultrasonic disruption.
8. The system according to claim 5, characterized in that The method for detecting the concentration of L-glutamine in the sample in step c is selected from any one or more of gas chromatography-mass spectrometry and immunoassay.
9. The system according to claim 3, characterized in that The differential diagnosis module includes comparing the data collected by the data collection module with the diagnostic criteria to determine the possibility of the subject being ill.
10. The system according to claim 9, characterized in that The diagnostic standard is to establish a control standard by analyzing sample data from a large number of healthy people. If the subject's data is significantly higher than the control standard, it is considered that the subject has a high possibility of suffering from type 2 diabetes.
